Boule Diagnostics AB (publ)

Stockholm Stock Exchange BOUL.ST

Boule Diagnostics AB (publ) Debt to Equity Ratio for the year ending December 31, 2023: 0.35

Boule Diagnostics AB (publ) Debt to Equity Ratio is 0.35 for the year ending December 31, 2023, a -14.84% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Boule Diagnostics AB (publ) Debt to Equity Ratio for the year ending December 31, 2022 was 0.41, a -21.86% change year over year.
  • Boule Diagnostics AB (publ) Debt to Equity Ratio for the year ending December 31, 2021 was 0.53, a 12.80% change year over year.
  • Boule Diagnostics AB (publ) Debt to Equity Ratio for the year ending December 31, 2020 was 0.47, a 1.11% change year over year.
  • Boule Diagnostics AB (publ) Debt to Equity Ratio for the year ending December 31, 2019 was 0.46, a 86.50% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Loading...
Stockholm Stock Exchange: BOUL.ST

Boule Diagnostics AB (publ)

CEO Mr. Torben Nielsen
IPO Date June 23, 2011
Location Sweden
Headquarters Domnarvsgatan 4
Employees 200
Sector Health Care
Industries
Description

Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. The company provides hematology analyzers, reagents, blood controls and calibrators, and reagents rotors, as well as cleaning products under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer and diagnostics systems under the Exigo brand. It sells its products directly in Sweden and the United States, as well as through distributors internationally. The company serves hospitals, clinics, laboratories, healthcare centers and veterinary clinics, and other diagnostics companies. It has operations in Sweden, the United States, Mexico, and Russia. The company was founded in 1956 and is headquartered in Spånga, Sweden.

Similar companies

BIOT.ST

Biotage AB (publ)

USD 11.98

-2.51%

CRAD-B.ST

C-Rad AB (publ)

USD 2.57

-0.02%

CEVI.ST

CellaVision AB (publ)

USD 18.76

3.89%

BIOG-B.ST

BioGaia AB (publ)

USD 9.75

-0.95%

CTT.ST

CTT Systems AB (publ)

USD 23.79

-0.07%

StockViz Staff

January 15, 2025

Any question? Send us an email